TP53 and hepatocellular carcinoma: To validate this observation of LR-DPVB efficacy and establish the clinical relevance between efficacy and key driver genes of human HCC, we exploited hydrodynamic tail-vein injections to generate a Trp53KO/MYCOE HCC model in which oncogenic MYC can be genomically integrated and Trp53 is deficient to recapitulate the features of HCC, as previously described29–31.